Epstein-Barr virus Latent Membrane Protein 1 and 2 peptide-Major Histocompatibility Complex (EBV LMP1/2 pMHC)

Epstein-Barr virus (EBV) Latent Membrane Protein 1 (LMP1) and Latent Membrane Protein 2 (LMP2) are viral oncogenes expressed in several human malignancies, including nasopharyngeal carcinoma (NPC), Hodgkin lymphoma, and NK/T-cell lymphomas (Taylor et al., 2015). These proteins are primarily intracellular, making them inaccessible to traditional antibody therapies; however, they are processed by the proteasome into short peptides and presented on the cell surface by Major Histocompatibility Complex (MHC) molecules, typically HLA-A*02:01 (Smith et al., 2017). These peptide-MHC (pMHC) complexes serve as highly specific targets for T-cell receptor (TCR)-based therapies and TCR-like antibodies (Lin et al., 2018). By targeting these complexes, therapeutic agents can selectively induce the lysis of EBV-transformed tumor cells while minimizing damage to healthy tissues that do not express these viral proteins. Current clinical strategies include the use of EBV-specific cytotoxic T lymphocytes (CTLs), TCR-engineered T cells (TCR-T), and bispecific T-cell engagers designed to recognize the unique spatial configuration of the viral peptide within the MHC groove (ClinicalTrials.gov, 2023).

Other names

EBV LMP1/2-HLA complexesLMP1/2-derived peptide-MHCEBV-specific pMHCEBV-specific pMHC complexesLMP1/2-HLA-A*02:01

T-cell receptor (TCR) binding and activation of cytotoxic T-lymphocytes (CTLs) to induce apoptosis in EBV-positive tumor cells (Smith et al., 2017).